ScreenerHero

LIMN Liminatus Pharma, Inc.

NAS · US · Healthcare · Biotechnology · liminatuspharma.com
3.880USD+4.86%Mkt Cap: 5.21M $P/E: —

Liminatus Pharma, Inc., a pre-clinical stage biopharmaceutical company, engages in the development of cancer therapies in the United States. It develops IBA101, a humanized anti CD47 monoclonal antibody, which is in Phas…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap5.21M USD
Enterprise Value3.40M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-10.21M USD
Revenue/Share—
Last Price3.880 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees1
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA-0.84
EV/Revenue—
P/S—
P/B13.75
EPS (TTM)-22.15
EPS (Forward)—
52W Range
0.095254% of range7.050
52W High7.050 USD
52W Low0.0952 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE103.99%
ROA-1990.37%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-9.96M USD
CapEx (TTM)13.11K USD
FCF Margin—
FCF Yield-191.99%
Net Debt-1.57M USD
Net Debt/EBITDA0.39
Balance Sheet
Debt/Equity-0.15
Current Ratio1.12
Quick Ratio0.99
Book Value/Sh0.27 USD
Cash/Share2.25 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Splits
Last Split1:50
Split DateAug 21, 2026
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.1.34M
Float919.25K
Insiders27.18%
Institutions1.41%
Short Interest
Short Ratio1.1d
Short % Float5.44%
Short % Out.4.38%
Shares Short58.82K
Short (prev mo.)206.62K
Technical
SMA 504.608 (-15.8%)
SMA 20014.27 (-72.8%)
Beta0.75
S&P 52W Chg16.45%
Avg Vol (30d)27.89K
Avg Vol (10d)27.65K
Technical Indicators
RSI (14)54.4
MACD0.2302
MACD Signal0.3138
MACD Hist.-0.0836
BB Upper4.348 USD
BB Middle3.779 USD
BB Lower3.210 USD
BB Width30.11%
ATR (14)0.3738 USD
Vol Ratio (20d)0.96x